QUICKLINKS AND VIEW OPITONS
Taking both a statin and a nonstatin to lower cholesterol increases risk of Parkinson’s by 95%
Tuesday, May 08, 2018 6:11 am Email this article
People taking both a statin and a nonstatin to lower cholesterol levels had a 95% increased risk of Parkinson’s compared to people taking neither according to a new study.
Nonstatin cholesterol-lowering drugs included fenoﬁbrate (Trilipix, Tricor, Triglide, Antara, Lipofen, Fibricor, Lofibra, and Fenoglide), ezetimibe (Zetia), and niacin.
This study found that the most popular statins increase the risk of Parkinson’s Disease by 58%.
These are the lipophilic statins, meaning that they dissolve in fats, which include atorvastatin (Lipitor), ﬂuvastatin (Lescol), lovastatin (Mevacor), pitavastatin (Livalo), simvastatin (Zocor).
Liu G, Sterling NW, Kong L, Lewis MM, Mailman RB, Chen H, Leslie D, and Huang X. Statins may facilitate Parkinson’s disease: Insight gained from a large, national claims database. Mov Disord, 2017 Apr 03; published online.
Author’s Contact Info
Xuemei Huang, MD, PhD
Professor & Vice Chair of Neurology,
Professor of Neurosurgery, Pharmacology, Radiology, & Kinesiology
Director, Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders
Co-Director, Center for Movement Disorders
Penn State University-Milton S. Hershey Medical Center
Department of Neurology, 500 University Drive
Hershey, PA 17033-0850
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.